Rezolute Announces Presentation at the 60th Annual ESPE Meeting
September 07, 2022 07:00 ET
|
Rezolute, Inc.
Data from Phase 2b RIZE Study in congenital hyperinsulinism will be presented in oral presentation REDWOOD CITY, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a...
Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer
June 01, 2022 07:00 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential...
Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress
May 12, 2022 16:05 ET
|
Rezolute, Inc.
Announced a $130 million registered direct offering and concurrent private placement Positive topline results from Phase 2b RIZE study of RZ358 exceeded expectations and demonstrated highly...
Rezolute to Host Corporate Update Call on May 4, 2022
May 04, 2022 16:01 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential...
Rezolute, Inc. Announces Closing of Registered Direct Offering
May 04, 2022 09:33 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential...
Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
May 01, 2022 23:25 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., May 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential...
Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism
May 01, 2022 14:00 ET
|
Rezolute, Inc.
Highly significant ~75% reduction in hypoglycemia events at anticipated therapeutic doses≥50% improvement in hypoglycemia in 100% of patients in high-dose cohort, with no adverse drug reactions or...
RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual Meeting on May 1, 2022
April 26, 2022 16:05 ET
|
Rezolute, Inc.
Rezolute to host conference call presentation and discussion of the data on Sunday, May 1 at 2:30 p.m. ET REDWOOD CITY, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a...
Rezolute Joins the Rare Disease Company Coalition
March 29, 2022 07:00 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential...
Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism
March 23, 2022 07:00 ET
|
Rezolute, Inc.
The RIZE study demonstrated highly significant improvements in hypoglycemia and good safety and tolerability Results to be presented in an oral presentation at a medical congress in 2Q 2022 REDWOOD...